(Reuters)—Five opioid manufacturers, including OxyContin maker Purdue Pharma LP, have paid more than $10 million to advocacy groups and doctors tied to them, many of whom amplified industry messages supporting the use of the painkillers, a U.S. Senate report said on Monday.1 The report, released by Sen. Claire McCaskill (D-Mo.), says groups who received the…
Articles by Natasha Yetman
Menopause Linked with Functional Decline in Rheumatoid Arthritis
NEW YORK (Reuters Health)—In women with rheumatoid arthritis (RA), menopause is associated with both functional decline and an acceleration of that decline, according to a longitudinal study from the U.S. However, several factors involving increased hormonal exposure were associated with less-severe functional decline in women with RA: ever having received hormonal replacement therapy (HRT), ever…
Family Planning Counseling & the Rheumatologist
Women with rheumatic diseases have unique reproductive health needs, and family planning counseling is a critical component to their overall healthcare. A new research review examines the barriers to patients with rheumatic disease receiving family planning counseling. Additionally, reviewers provide rheumatologists with practical suggestions to optimize communication with patients, as well as address the effect of medications and the effectiveness of contraception…
Baseline Bone Measures Predict Risk of Fragility Fracture in Postmenopausal
NEW YORK (Reuters Health)—Baseline measures of bone density, microarchitecture and strength predict the risk of fragility fractures in postmenopausal women, according to results from the Calgary CaMOS cohort. Changes in bone health were not associated with fracture risk, however, said Dr. Lauren A. Burt from the University of Calgary, Canada, who worked on the study….
New Recommendations Guide Imaging in Large-Vessel Vasculitis
NEW YORK (Reuters Health)—Patients with suspected large-vessel vasculitis (LVV) should undergo early imaging, the European League Against Rheumatism (EULAR) advises in a new report presenting a dozen evidence-based recommendations for the use of imaging in primary LVV. Ultrasound should be the first choice for giant-cell arteritis (GCA), while MRI should take precedence for Takayasu arteritis…
ACGME Milestones Debated at ACR: Does the Milestones System Ask too many Questions?
Milestones are at the core of the current system designed to evaluate medical residency and fellowship programs and their participants. But are all milestones meaningful for medical education? This idea was at the center of a debate during the 2017 ACR/ARHP Annual Meeting, during which speakers explored the advantages and drawbacks of using training milestones for rheumatology fellowships…
U.S. Telehealth Industry Eyes Medicare for Its Next Big Check
(Reuters)—After years of lobbying in Washington, U.S. telehealth providers have the first hints that the dam could break on public funding for an industry they say could save taxpayers billions. Four bills that could be signed into law over the next year carry the solutions to barriers that have prevented the U.S.s’ huge over-65 health…
Amazon, Berkshire, JPMorgan Partner to Cut U.S. Healthcare Costs
NEW YORK (Reuters)—Amazon.com Inc., Berkshire Hathaway Inc. and JPMorgan Chase & Co. said on Tuesday they will form a company to cut health costs for hundreds of thousands of their employees, setting up a major challenge to an inefficient U.S. healthcare system. The move by three of the best-known U.S. business leaders—Amazon’s Jeff Bezos, Berkshire’s…
Synthetic DMARDs May Blunt Pneumococcal Vaccine Response in Systemic Sclerosis
NEW YORK (Reuters Health)—Pneumococcal vaccination yields a satisfactory antibody response in patients with systemic sclerosis (SSc), but synthetic disease-modifying antirheumatic drugs (DMARDs) might reduce the vaccine response in these individuals, according to a report from Sweden. The prospective study, published online Jan. 8 in Rheumatology, evaluated the response to either pneumococcal conjugate vaccine (PCV13) or…
U.S. Appeals Court Invalidates J&J Patent on Remicade
(Reuters)—A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson patent on its blockbuster rheumatoid arthritis drug, Remicade (infliximab), limiting J&J’s ability to seek damages from Pfizer Inc. over its launch of a lower-cost version of the drug. The U.S. Circuit Court of Appeals for the Federal Circuit affirmed…
- « Previous Page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- …
- 97
- Next Page »